| [1] |
Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy [J]. Cell, 2017, 168(4): 707-723.
|
| [2] |
Thompson JA. New NCCN guidelines: recognition and management of immunotherapy-related toxicity [J]. J Natl Compr Cancer Netw, 2018, 16(5S): 594-596.
|
| [3] |
Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors [J]. Kidney Int, 2016, 90(3): 638-647.
|
| [4] |
Perazella MA, Sprangers B. Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations [J]. Clin Kidney J, 2021, 14(5): 1301-1306.
|
| [5] |
Seethapathy H, Zhao S, Chute DF, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors [J]. Clin J Am Soc Nephrol, 2019, 14(12): 1692-1700.
|
| [6] |
Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review [J]. Am J Nephrol, 2017, 45(2): 160-169.
|
| [7] |
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity′s roles in cancer suppression and promotion [J]. Science, 2011, 331(6024): 1565-1570.
|
| [8] |
Borst J, Busselaar J, Bosma DMT, et al. Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy [J]. Eur J Immunol, 2021, 51(8): 1911-1920.
|
| [9] |
Wherry EJ. T cell exhaustion [J]. Nat Immunol, 2011, 12(6): 492-499.
|
| [10] |
Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study [J]. J Am Soc Nephrol, 2020, 31(2): 435-446.
|
| [11] |
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer [J]. N Engl J Med, 2019, 381(21): 2020-2031.
|
| [12] |
Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? [J]. Kidney Int, 2020, 97(1): 62-74.
|
| [13] |
Blank ML, Parkin L, Paul C, et al. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use [J]. Kidney Int, 2014, 86(4): 837-844.
|
| [14] |
Chute DF, Zhao S, Strohbehn IA, et al. Incidence and predictors of CKD and estimated GFR decline in patients receiving immune checkpoint inhibitors [J]. Am J Kidney Dis, 2021, Epub ahead of print.
|
| [15] |
Shimamura Y, Watanabe S, Maeda T, et al. Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study [J]. Clin Exp Nephrol, 2021, 25(5): 479-487.
|
| [16] |
Scanvion Q, Béné J, Gautier S, et al. Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database [J]. Oncoimmunology, 2020, 9(1): 1722022.
|
| [17] |
Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis [J]. N Engl J Med, 2009, 361(2): 211-212.
|
| [18] |
Izzedine H, Gueutin V, Gharbi C, et al. Kidney injuries related to ipilimumab [J]. Invest New Drugs, 2014, 32(4): 769-773.
|
| [19] |
Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade [J]. N Engl J Med, 2016, 375(18): 1749-1755.
|
| [20] |
Ding H, Wu X, Gao W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis [J]. Clin Immunol, 2005, 115(2): 184-191.
|
| [21] |
Hakroush S, Kopp SB, Tampe D, et al. Variable expression of programmed cell death protein 1-ligand 1 in kidneys independent of immune checkpoint inhibition [J]. Front Immunol, 2021, 11: 624547.
|
| [22] |
Jaworska K, Ratajczak J, Huang L, et al. Both PD-1 ligands protect the kidney from ischemia reperfusion injury [J]. J Immunol, 2015, 194(1): 325-333.
|
| [23] |
Kim SH, Park SJ, Han KH et al. Pathogenesis of minimal change nephrotic syndrome: an immunological concept [J]. Korean J Pediatr, 2016, 59(5): 205-211.
|
| [24] |
Hou Q, Xu H. Rational discovery of response biomarkers: candidate prognostic factors and biomarkers for checkpoint inhibitor-based immunotherapy [J]. Adv Exp Med Biol, 2020, 1248: 143-166.
|
| [25] |
Franzin R, Netti GS, Spadaccino F, et al. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand? [J]. Front Immunol, 2020, 11: 574271.
|
| [26] |
Izzedine H, Mathian A, Champiat S, et al. Renal toxicities associated with pembrolizumab [J]. Clin Kidney J, 2019, 12(1): 81-88.
|
| [27] |
Kitchlu A, Jhaveri KD, Wadhwani S, et al. A systematic review of immune checkpoint inhibitor-associated glomerular disease [J]. Kidney Int Rep, 2021, 6(1): 66-77.
|
| [28] |
Takahashi N, Tsuji K, Tamiya H, et al. Goodpasture′s disease in a patient with advanced lung cancer treated with nivolumab: an autopsy case report [J]. Lung Cancer, 2018, 122: 22-24.
|
| [29] |
Del Bello A, Zakaroff AG, Meyer N, et al. Cytokine storm induced by a PD1 inhibitor in a renal transplant patient [J]. Am J Transplant, 2021, 21(7): 2616-2618.
|
| [30] |
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline [J]. J Clin Oncol, 2018, 36(17): 1714-1768.
|
| [31] |
Isik B, Alexander MP, Manohar S, et al. Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events [J]. Kidney Int Rep, 2021, 6(4): 1022-1031.
|
| [32] |
Sun PP, Zhou XJ, Su JQ, et al. Urine macrophages reflect kidney macrophage content during acute tubular interstitial and glomerular injury [J]. Clin Immunol, 2019, 205: 65-74.
|
| [33] |
Kim MG, Lim K, Lee YJ, et al. M2 macrophages predict worse long-term outcomes in human acute tubular necrosis [J]. Sci Rep, 2020, 10(1): 2122.
|
| [34] |
Herrmann SM, Perazella MA. Immune checkpoint inhibitors and immune-related adverse renal events [J]. Kidney Int Rep, 2020, 5(8): 1139-1148.
|
| [35] |
Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates [J]. J Clin Oncol, 2010, 28(19): 3167-3175.
|